AMD diagnostic based on genetic variations licensed

Article

Ophtherion has licensed the worldwide rights to develop diagnostic products for age-related macular degeneration (AMD) associated with specific variations in genes on Chromosome 10, from the University of Pittsburgh, USA.

Ophtherion has licensed the worldwide rights to develop diagnostic products for age-related macular degeneration (AMD) associated with specific variations in genes on Chromosome 10, from the University of Pittsburgh, USA.

In 2005, researchers from the University of Pittsburgh published their findings relating to a link between Chromosome 10, specifically the LOC387715 and HTRA1 genes, and AMD in the American Journal of Human genetics.

It is hoped that genetics tests could be developed from the research that will identify people at risk of developing AMD, allowing medical professionals to intervene more aggressively at the very early stages of the disease.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.